Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

Deals > All

Total search results: 10135 | Ordered by Date (descending)
1 2 3 ... 100 101 102  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
eGenesis–Bayer: investment, 201911 financing round Series B totalling $100m incl new + co-investor Leaps by Bayer 2019-11-07
eGenesis–Fresenius: investment, 201911 financing round Series B totalling $100m incl lead investor Fresenius Medical Care Ventures 2019-11-07
eGenesis–SEVERAL: investment, 201911 financing round Series B $100m led by Fresenius Medical Care Ventures 2019-11-07
eGenesis–Wellington Partners: investment, 201911 financing round Series B totalling $100m incl new + co-investor Wellington Partners 2019-11-07
Artios Pharma–Univ Texas: ATR inhibitors, 201911– license excl ww to small-molecula ATR inhibitor programme from MD Anderson + ShangPharma Innovation 2019-11-06
Greenough–KDM Communications: investment, 201911 merger combination to provide transatlantic PR services 2019-11-06
Rentschler–General Electric: single-use bioreactor, 201911–202006 supply Xcellerex XDR-500 bioreactor for Rentschler facility in Milford, MA 2019-11-06
Vifor Pharma–Evotec: drug r+d, 201911– collab establishment 50/50 joint venture for nephrology treatments using NURTuRE biobank + PanHunter s/w 2019-11-06
Poxel–IPF Partners: credit, 201911–201412 bond loan up to €30m in three tranches 11/19 + 3/20 + 12/21 2019-11-05
Pieris–BVF Partners: investment, 201911 private placement totalling $32m incl existing + lead investor BVF Partners 2019-11-04
Pieris–SEVERAL: investment, 201911 private placement $32m w 9.015m units (shares + warrants) at $3.55/unit led by BVF Partners 2019-11-04
Fitbit–Alphabet: investment, 201911– acquisition of Fibit Inc by Google LLC for $7.35/share in cash valuing Fibtit at $2.1b ANNOUNCED 2019-11-01
Roivant–Sumitomo: investment, 201910 acquisition 10% stake in Roivant by Sumitomo Dainippon Pharma in connection w strategic alliance 2019-10-31
Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Altavant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance 2019-10-31
Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Enzyvant Therapeutics by Sumitomo Dainippon Pharma as part of strategic alliance 2019-10-31
Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Myovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance 2019-10-31
Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Spirovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance 2019-10-31
Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Urovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance 2019-10-31
Sumitomo–Roivant: drug development, 201910– collab strategic alliance $3b upfront incl transfer of 5 vants to Sumitomo Dainippon Pharma 2019-10-31
genOway–Institut Pasteur: transgenic anmials, 201910– license extension from IP + Cellectis to genOway to take legal actions against infringement 2019-10-30
Disc Medicine–AbbVie: therapeutics antibodies, 201910– license €na ww excl to series of hemojuvelin antagonist MAbs from AbbVie 2019-10-29
Disc Medicine–Novo Group: investment, 201910 financing round Series A totalling $50m incl new + lead investor Novo Holdings A/S 2019-10-29
Disc Medicine–SEVERAL: investment, 201910 financing round Series A $50m led by Novo Holdings A/S 2019-10-29
Centogene–SEVERAL: investment, 201910– IPO $60m with 4m+600k comon shares at $14-$16/share at Nasdaq Global Market ANNOUNCED 2019-10-28
i-Dositecno–SP Industries: investment, 201910 acquisition of assets of i-Dositecno by SP Industries 2019-10-28
SMS-Oncology–Cato Research: investment, 201910 merger €na 2019-10-28
Pepticom–Chartered Group: investment, 201910 Series A investment of $5m by the Chartered Group 2019-10-24
OpGen–SEVERAL: investment, 201910 underwritten public offering $9.4m 2019-10-23
Encycle Therapeutics–Zealand Pharma: investment, 201910 acquisition of Encycle Therapeutics for up to $80m 2019-10-22
MCG Motion Capture–Akampion: public relations, 201910 service existent by Akampion 2019-10-22
MCG Motion Capture–Biotech Alliances International: investment banking, 201910– service excl for planned $15m Series A Round of MCG 2019-10-22
MCG Motion Capture–SEVERAL: investment, 201910– PLANNED financing round Series A $15m 2019-10-22
Arcutis Biotherapeutics–HBM: investment, 201910 financing round Series C totalling $94.5m incl new + lead investor HBM Healthcare Investments 2019-10-21
Arcutis Biotherapeutics–OrbiMed: investment, 201910 financing round Series C totalling $94.5m incl existing + co-investor OrbiMed 2019-10-21
Arcutis Biotherapeutics–SEVERAL: investment, 201910 financing round Series C $94.5m led by HBM Healthcare Investments 2019-10-21
Bavarian Nordic–GSK: vaccines, 201910 acquisition up to €796m incl €301m upfront of manufacturing + global rights to Rabipur/RabAvert + Encepur by BN 2019-10-21
Danaher–Sartorius: investment, 201910– acquisition $750m three life science businesses by Sartorius part of regulatory clearance for GE/Danaher deal 2019-10-21
Plexium–Merck (DE): investment, 201910 financing round Series A totalling $28m incl co-investor M Ventures 2019-10-17
Plexium–SEVERAL: investment, 201910 financing round Series A $28m co-led by DCVC Bio + The Column Group 2019-10-17
Sofinnova–SEVERAL: investment, 201910 closing €333m of Sofinnova Capital IX fund 2019-10-17
Adaptate Biotherapeutics–Abingworth: investment, 201910 investment by Abingworth + Takeda facilitating spin-out of Adaptate from GammaDelta Tx 2019-10-16
Adaptate Biotherapeutics–SEVERAL: investment, 201910 spin-out from GammaDelta Therapeutics with investment from Abingworth & Takeda Pharmaceutical 2019-10-16
Adaptate Biotherapeutics–Takeda: investment, 201910 investment by Abingworth + Takeda with time-limited option to acquire Adatpate for Takeda 2019-10-16
Amarna Therapeutics–Flerie Invest: investment, 201910 financing round totalling €10m incl lead investor Flerie Invest AB + incl RVO innovation credit 2019-10-16
Amarna Therapeutics–Netherlands (govt): credit, 201910 financing round totalling €10m incl substantial innovation credit from RVO.nl 2019-10-16
Amarna Therapeutics–PERSON: investment, 201910 financing round totalling €10m incl existing + co-investor Pim Berger + incl RVO innovation credit 2019-10-16
Amarna Therapeutics–SEVERAL: investment, 201910 financing round €10m led by Flerie Invest AB + incl innovation credit from RVO.nl 2019-10-16
Healx–Amadeus Capital: investment, 201910 financing round Series B totalling $56m incl exisiting + co-investor Amadeus Capital Partners 2019-10-16
Healx–Atomico: investment, 201910 financing round Series B totalling $56m incl new + lead investor Atomico 2019-10-16
Healx–Balderton Capital: investment, 201910 financing round Series B totalling $56m incl exisiting + co-investor Balderton Capital 2019-10-16
Healx–btov Partners: investment, 201910 financing round Series B totalling $56m incl new + co-investor btov Partners 2019-10-16
Healx–Global Brain: investment, 201910 financing round Series B totalling $56m incl new + co-investor Global Brain 2019-10-16
Healx–Intel: investment, 201910 financing round Series B totalling $56m incl new + co-investor Intel Capital 2019-10-16
Healx–PERSON: investment, 201910 financing round Series B totalling $56m incl exisiting + co-investor Jonathan Milner 2019-10-16
Healx–SEVERAL: investment, 201910 financing round Series B $56m led by new investor Atomico 2019-10-16
Abalos Therapeutics–Boehringer: investment, 201910 financing round Series A totalling €12m invl co-lead investor BIVF 2019-10-15
Abalos Therapeutics–High-Tech Gründerfonds: investment, 201910 financing round Series A totalling €12m incl co-investor HTGF 2019-10-15
Abalos Therapeutics–North-Rhine Westphalia (govt): investment, 201910 financing round Series A totalling €12m incl co-investor NRW.BANK 2019-10-15
Abalos Therapeutics–North-Rhine Westphalia (govt): investment, 201910 financing round Series A totalling €12m incl co-lead investor Gründerfonds Ruhr 2019-10-15
Abalos Therapeutics–SEVERAL: investment, 201910 financing round Series A €12m co-led by BIVF + Gründerfonds Ruhr 2019-10-15
Abalos Therapeutics–Trophic Communications: public relations, 201910 service existent by Trophic 2019-10-15
CRISPR Therapeutics–KSQ Therapeutics: CRISPR-based cell therapy, 201910– cross-licensing €na genome editing + CAR-T cell therapy IP 2019-10-15
Mogrify–24Haymarket: investment, 201910 financing round Series A first closing totalling $16m incl existing + co-investor 24Haymarket 2019-10-14
Mogrify–Ahren Innovation Capital: investment, 201910 financing round Series A first closing totalling $16m incl existing + lead investor Ahren 2019-10-14
Mogrify–Parkwalk Advisors: investment, 201910 financing round Series A first closing totalling $16m incl new + co-investor Parkwalk 2019-10-14
Mogrify–SEVERAL: investment, 201910 financing round Series A first closing $16m led by existing investor Ahren Innovation Capital 2019-10-14
Mogrify–Univ Bristol: investment, 201910 financing round Series A first closing totalling $16m incl new + co-investor Univ Bristol Enterprise Fund III 2019-10-14
Biocon–Evotec: biosimilars, 201910– license €na to Biocon Biologics for pre-clinical biosimilar asset of Just-Evotec Biologics 2019-10-10
FloDesign Sonics–Merck (DE): investment, 201910 acquisition €na by Merck 2019-10-10
Ra Pharmaceuticals–UCB: investment, 201910– acquisition $2.5b in cash for $48/share incl acquired net cash of $315m ANNOUNCED 2019-10-10
Celmatix–Evotec: drug discovery services, 201910– collab €na developm pre-clinical programs for reproductive women’s health 2019-10-09
D.I. Biotech–Solentim: laboratory equipment, 201910 distribution existent of Solentim’s cell line developm instruments in Korea by D.I. Biotech Ltd 2019-10-09
Imperial Life Sciences–Solentim: laboratory equipment, 201910 distribution existent of Solentim’s cell line developm instruments in India by Imperial 2019-10-09
Kiko Tech–Solentim: laboratory equipment, 201910 distribution existent of Solentim’s cell line developm instruments in Japan by Kiko Tech Co Ltd 2019-10-09
N-Side–Sciad Communications: public relations, 201910 service existent by Sciad 2019-10-09
Novo Group–Bluebird Bio: gene therapy, 201910–202209 collab r+d 3y utilising megaTAL technology to develop hemophilia A gene therapies 2019-10-09
Optec (RU)–Solentim: laboratory equipment, 201910 distribution existent of Solentim’s cell line developm instruments in Russia by Optec LLC 2019-10-09
Parexel–Roivant: healthcare informatics, 201910– collab with Datavant multi-year strategic alliance integration of real-world with clinical trial data 2019-10-09
Trio Biotech–Solentim: laboratory equipment, 201910 distribution existent of Solentim’s cell line developm instruments in China by Trio Biotech Co Ltd 2019-10-09
Unimed Healthcare–Solentim: laboratory equipment, 201910 distribution existent of Solentim’s cell line developm instruments in Taiwan by Unimed 2019-10-09
Bayer–RIKEN: drug discovery, 201910– strategic collaboration incl drug target discovery of Bayer Open Innovation Center Japan + RIKEN Innovation 2019-10-08
GSK–Lyell Immunopharma: cancer cell therapy, 201910–202409 collab 5y developm of technologies to improve cancer cell therapies 2019-10-08
Merck (US)–4D Pharma: microbiomic treatments, 201910– collab r+d Live Biotherapeutics as vaccines 2019-10-08
Vivoryon–MC Services: public relations, 201910 service existent by MC Services 2019-10-08
Vivoryon–MorphoSys: investment, 201910– public rights offering totalling €30m–€70m incl €15m but limited to max 19.98% holding from MorphoSys AG 2019-10-08
Vivoryon–SEVERAL: investment, 201910– public rights offering €30m–€70m incl Claus Chrisitansen + Den Danske Forskningsfond + T&W Holding + MorphoSys 2019-10-08
4SC–SEVERAL: investment, 201910 capital increase €22.4m net €22m with 10.65m new shares at €2.1/share with subscription rights 2019-10-07
4SC–Strüngmann Group: investment, 201910 capital increase totalling €22.4m net €22m incl subscription rights for Santo Holding + ATS 2019-10-07
Dalhousie Univ–Thermo Fisher: mass spectrometer, 201910 supply C$1.3m of Orbitrap Fusion MS system to MS + Proteomics Core Faclity 2019-10-07
Illumina–Qiagen: sequencing-based IVD tests, 201910–2034 collab 15y strategic alliance combining sequencing technology + assays + automation + s/w 2019-10-07
MiroBio–Advent Venture Partners: investment, 201910 financing round Series A totalling £27m incl co-investor Advent Life Sciences 2019-10-07
MiroBio–GSK: investment, 201910 financing round Series A totalling £27m incl co-investor SR One 2019-10-07
MiroBio–Samsara Biocapital: investment, 201910 financing round Series A totalling £27m incl co-lead investor Samsara Biocapital 2019-10-07
MiroBio–SEVERAL: investment, 201910 financing round Series A £27m co-led by Oxford Sciences Innovation + Samsara Biocapital 2019-10-07
MiroBio–Univ Oxford: investment, 201910 financing round Series A totalling £27m incl co-lead investor Oxford Sciences Innovation 2019-10-07
Rentschler–Sumitomo: biologics contract manufacturing, 201910– collab expansion SPI supports marketing + delivery of Rentschler CDMO services in Japan 2019-10-04
Aeovian Pharmaceuticals–Apollo Ventures: investment, 201910 financing round Series A totalling $37m incl founding + co-investor Apollo Health Ventures 2019-10-03
Aeovian Pharmaceuticals–Evotec: investment, 201910 financing round Series A totalling $37m incl founding + co-investor Evotec 2019-10-03
Aeovian Pharmaceuticals–SEVERAL: investment, 201910 financing round Series A $37m led by VenBio + Sofinnova Investments 2019-10-03
Aeovian Pharmaceuticals–Sofinnova: investment, 201910 financing round Series A totalling $37m incl new + co-lead investor Sofinnova Investments 2019-10-03
1 2 3 ... 100 101 102  next pagenext page



Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture EBD Group BIO-Europe 2019 Hamburg Germany BEU2019 650x80px

» top